Skip to main content

Table 2 Key studies of TNF-blocker therapy in psoriatic arthritis

From: Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future

     Outcomes reported
        Dactylitis   Function      
Therapy Published study Primary outcome Radiologic outcomes Joint Skin Nail   Enthesitis   QoL Pain EMS Fatigue CRP/ ESR
Infliximab Antoni and colleagues [59], Kavanaugh and colleagues [52] ACR20 at week 16 mvdH-SS at week 50 x x   x x x   x    x
Infliximab Antoni and colleagues [60], van der Heijde and colleagues [56] ACR20 at week 14 mvdH-SS at weeks 24 and 54 x x   x x x   x x   x
Etanercept Mease and colleagues [61] PsARC at week 12 NA x x     x   x    x
Etanercept Mease and colleagues [58] ACR20 at week 12 mTSS at months 6 and 12 x x     x   x    x
Adalimumab Mease and colleagues [54] ACR20 at week 12 mTSS at week 24 x x   x x x x    x  
Golimumab Kavanaugh and colleagues [62] ACR20 at week 14 NA x x x x x x      
  1. ACR20, American College of Rheumatology 20% improvement; CRP/ESR, C-reactive protein/erythrocyte sedimentation rate, EMS, early morning stiffness; mvdH-SS, modified van der Heijde–Sharp score; mTSS, modified total Sharp score; NA, not available; PsARC, Psoriasis Arthritis Response Criteria; QoL, quality of life.